Ofatumumab versus single agent Rituxan for patients who have relapsed after having treatment containing Rituxan.
Patients must have a WHO grade of 1,2,3 A and have had a partial response or complete response that lasted at least 6 months. Patients must have two lesions greater than 1.5 cm or one lesion greater than 2 cm. Patients must have massive or progressive organomegaly OR cytopenia OR lymphoma related symptoms OR progressive or massive lymphadenopathy.
Exclusions include, but are not limited to, Positive Hepatitis B, active liver or biliary disease, chronic or current infection, stem cell transplant or radioimmunotherapy within the last six months.
“I have an aggressive type of cancer and it was time to take drastic measures…When I heard about the trial from Dr. Hodge, I felt privileged to have this type of care and the chance to help others who may be in my shoes one day.”